StockData

Neuroone Medical Technologies vs InspireMD

NMTC and NSPR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NMTC and NSPR compare

InspireMD is the larger company, worth 4.4 times as much as Neuroone Medical Technologies ($29.9M against $6.8M).

InspireMD grew revenue faster over the last twelve months (53.4% versus 42.8% for Neuroone Medical Technologies).

Neuroone Medical Technologies keeps more of each dollar of sales as profit, with a net margin of −78.6% compared with −484% at InspireMD.

Neuroone Medical Technologies scores higher on the StockData Score (11 against 10 for InspireMD), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNMTCNSPR
Size and price
Market cap$6.8M$29.9M
Share price$0.745$0.644
Change, 1 year−83.1%−64.0%
Change, 5 years−94.9%−82.7%
Beta (5Y)0.710.46
Employees18127
StockData Score
Total score11 (better)10
Valuation score33
Growth score22
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S0.7× (better)2.8×
P/B1.8×1.0× (better)
FCF yield−106% (better)−142%
Fair value$3.60$1.41
Margin of safety79.3% (better)54.4%
Growth
Revenue growth (TTM)42.8%53.4% (better)
Revenue growth, 5Y average–29.3%
Profitability
Gross margin55.6% (better)18.1%
Operating margin−83.4% (better)−494%
Net margin−78.6% (better)−484%
FCF margin−75.6% (better)−392%
Return on equity−125% (better)−203%
Return on invested capital−672% (better)−4320%
Financial health
Debt / equity0.000.00
Current ratio2.843.80 (better)
Altman Z-score−19.38−11.98 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.7%53.6%
Held by insiders85.4%31.6%
Insider net buying, 12 months$682K (better)$369K
Short interest, % of float15.6%0.79%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.